Abstract:P21-activated kinase 4 (PAK4) is a serine/threonine protein kinase, which is associated with many cancer diseases, and thus being considered as a potential drug target. In this study, three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking and molecular dynamics (MD) simulations were performed to explore the structure-activity relationship of a series of pyrropyrazole PAK4 inhibitors. The statistical parameters of comparative molecular field analysis (CoMFA, Q2 = 0.837, R2 = 0.990, and R2pred = 0.967) and comparative molecular similarity indices analysis (CoMSIA, Q2 = 0.720, R2 = 0.972, and R2pred = 0.946) were obtained from 3D-QSAR model, which exhibited good predictive ability and significant statistical reliability. The binding mode of PAK4 with its inhibitors was obtained through molecular docking study, which indicated that the residues of GLU396, LEU398, LYS350, and ASP458 were important for activity. Molecular mechanics generalized born surface area (MM-GBSA) method was performed to calculate the binding free energy, which indicated that the coulomb, lipophilic and van der Waals (vdW) interactions made major contributions to the binding affinity. Furthermore, through 100 ns MD simulations, we obtained the key amino acid residues and the types of interactions they participated in. Based on the constructed 3D-QSAR model, some novel pyrropyrazole derivatives targeting PAK4 were designed with improved predicted activities. Pharmacokinetic and toxicity predictions of the designed PAK4 inhibitors were obtained by the pkCSM, indicating these compounds had better absorption, distribution, metabolism, excretion and toxicity (ADMET) properties. Above research provided a valuable insight for developing novel and effective pyrropyrazole compounds targeting PAK4.Communicated by Ramaswamy H. SarmaThe 3D-QSAR on pyrropyrazole PAK4 inhibitors was studied for the first time and the constructed 3D-QSAR model exhibited good predictive ability and significant statistical reliability.Molecular docking and molecular dynamics simulations were performed to obtain the binding mechanism, and the binding free energy was calculated by MM-GBSA method.Based on the CoMFA and CoMSIA models, a series of pyrropyrazole derivatives with potential better bioactivities were designed.ADMET properties of the newly designed PAK4 inhibitors were predicted, and these inhibitors exhibited better ADMET properties. three-dimensional quantitative structure-activity relationshipabsorption, distribution, metabolism, excretion, toxicitycomputer-aided drug designcomparative molecular field analysiscomparative molecular similarity indices analysisF-statistic valueshydrogen bond acceptorhydrogen bond donorlimited memory Broyden Fletcher Goldfarb Shannoleave one outmaximum common substructuremolecular dynamicsmolecular mechanics generalized-born surface areanormal pressure temperatureoptimal number of componentspartial least squarecross-validated correlation coefficient; R2, noncross-validated correlation coefficient; R2predictive correlation coefficientroot-mean-square deviationroot mean square errorstandard error of estimatesimple point chargestandard deviation and coefficientvan der WaalseXtended electron distribution.

QSAR Study of Pyrazolo[1,5-A]pyrimidine Derivative Inhibitors of Chk1

Checkpoint Kinase Inhibitor AZD7762 Enhance Cisplatin-Induced Apoptosis in Osteosarcoma Cells.

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

QSAR Studies of Imidazopyridine Derivatives As Et-PKG Inhibitors Using the PSO-SVM Approach

Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors

Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors

QSAR study of tetrahydropteridin derivatives as polo-like kinase 1(PLK1) Inhibitors with molecular docking and dynamics study

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Synthesis and Biological Evaluation of 2,6-Disubstituted-9h-purine, 2,4-Disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine Analogues As Novel CHK1 Inhibitors.

Theoretical investigation on QSAR of (2-Methyl-3-biphenylyl) methanol analogs as PD-L1 inhibitor

Discovery of pyrido[3,2- d ]pyrimidin-6(5 H )-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy

In silico studies on p21-activated kinase 4 inhibitors: comprehensive application of 3D-QSAR analysis, molecular docking, molecular dynamics simulations, and MM-GBSA calculation

Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques.

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

A Linear and Nonlinear QSAR Analysis of Benzimidazole Derivative XY123 in Prostate Cancer Treatment

A novel non-linear approach for establishing a QSAR model of a class of 2-Phenyl-3-(pyridin-2-yl) thiazolidin-4-one derivatives

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

QSAR study of flavonoids inhibitors of the PIM-1 kinase

Discovery of novel pyrrolo[2,3-d]pyrimidine derivatives as anticancer agents: virtual screening and molecular dynamic studies

Study of PARP inhibitors for breast cancer based on enhanced multiple kernel function SVR with PSO

QSAR study of fiavonoids derivatives as p56lck protein tyrosine kinase inhibitors using GA-SVM